EP Patent

EP4230196A1 — Compounds for use in the treatment of dystrophinopathies

Assigned to Som Innovation Biotech SA · Expires 2023-08-23 · 3y expired

What this patent protects

The present invention relates to a compound selected from the group consisting of Veliflapon, Difenpiramide, Amopyroquine, Cloricromen, Alpelisib, Benorilate, Xipamide, Fabomotizole and Altizide, or a pharmaceutically acceptable salt thereof, and to combinations thereof, for use …

USPTO Abstract

The present invention relates to a compound selected from the group consisting of Veliflapon, Difenpiramide, Amopyroquine, Cloricromen, Alpelisib, Benorilate, Xipamide, Fabomotizole and Altizide, or a pharmaceutically acceptable salt thereof, and to combinations thereof, for use in the treatment or prevention of a dystrophinopathy.

Drugs covered by this patent

Patent Metadata

Patent number
EP4230196A1
Jurisdiction
EP
Classification
—
Expires
2023-08-23
Drug substance claim
No
Drug product claim
No
Assignee
Som Innovation Biotech SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.